丙戊酸镁治疗双相情感障碍对患者血清总胆红素、白蛋白、炎性因子水平和生活质量的影响
|
摘要
目的分析丙戊酸镁治疗双相情感障碍对患者血清总胆红素(TBIL)、白蛋白、炎性因子水平和生活质量的影响。方法选取广西壮族自治区脑科医院2017年8月～2018年7月收治的双相情感障碍100例患者的临床资料进行回顾性分析,按照治疗方法不同分为对照组和观察组,每组各50例。对照组患者采用碳酸锂治疗,观察组患者采用丙戊酸镁治疗,分析两组患者的治疗效果。结果观察组患者总有效率高于对照组,差异有统计学意义(P <0.05)。两组患者治疗后肿瘤坏死因子-α(TNF-α)、尿酸(UA)水平较治疗前下降,TBIL、血清白蛋白较治疗前上升,且观察组患者治疗后TNF-α、UA水平低于对照组,TBIL、血清白蛋白水平高于对照组,差异均有统计学意义(均P <0.05)。两组患者治疗后汉密尔顿抑郁量表(HAMD)评分、狂躁量表(BRMS)评分较治疗前下降,健康调查简表(SF-36)评分较治疗前上升,且观察组患者HAMD评分、BRMS评分低于对照组,SF-36评分高于对照组,差异均有统计学意义(均P <0.05)。观察组患者不良反应发生率低于对照组,差异有统计学意义(P <0.05)。结论丙戊酸镁治疗双相情感障碍患者效果明显,改善患者生活质量,减轻狂躁及抑郁情况,降低不良反应发生率,值得临床推广应用。
Objective To analyze the effect of magnesium valproate on serum total bilirubin(TBIL), albumin, inflammatory factor level and quality of life in patients with bipolar affective disorder. Methods The clinical data of 100 patients with bipolar affective disorder admitted in Guangxi Zhuang Autonomous Region Brain Hospital from August 2017 to July 2018 were retrospectively analyzed and divided into control group and observation group according to different treatment methods, each group had 50 cases. The patients in the control group were treated with lithium carbonate, and the patients in the observation group were treated with magnesium valproate, to analyze the effect of the two groups after treatment. Results The total effective rate in the observation group was significantly higher than that in the control group, the difference was statistically significant(P < 0.05). After treatment, the levels of tumor necrosis factor-α(TNF-α) and uric acid(UA) decreased, TBIL, serum albumin increased after treatment, and the levels of TNF-α and UA in the observation group were lower than those in the control group, and the serum albumin level of TBIL was higher than that of the control group, and the differences were statistically significant(all P < 0.05). After treatment, the scores of hamilton depression scale(HAMD), mania scale(BRMS) and health survey summary form(SF-36) were decreased, and the HAMD and BRMS scores of the patients in the observation group were lower than those of the control group, and the SF-36 score was higher than that of the control group, and the differences were statistically significant(all P < 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group, the difference was statistically significant(P < 0.05). Conclusion The effect of magnesium valproate on bipolar affective disorder patients is obvious. It can improve the quality of life, reduce the condition of mania and depression, and reduce the incidence of adverse reactions. It is worth popularizing and applying in clinic.
Objective To analyze the effect of magnesium valproate on serum total bilirubin(TBIL), albumin, inflammatory factor level and quality of life in patients with bipolar affective disorder. Methods The clinical data of 100 patients with bipolar affective disorder admitted in Guangxi Zhuang Autonomous Region Brain Hospital from August 2017 to July 2018 were retrospectively analyzed and divided into control group and observation group according to different treatment methods, each group had 50 cases. The patients in the control group were treated with lithium carbonate, and the patients in the observation group were treated with magnesium valproate, to analyze the effect of the two groups after treatment. Results The total effective rate in the observation group was significantly higher than that in the control group, the difference was statistically significant(P < 0.05). After treatment, the levels of tumor necrosis factor-α(TNF-α) and uric acid(UA) decreased, TBIL, serum albumin increased after treatment, and the levels of TNF-α and UA in the observation group were lower than those in the control group, and the serum albumin level of TBIL was higher than that of the control group, and the differences were statistically significant(all P < 0.05). After treatment, the scores of hamilton depression scale(HAMD), mania scale(BRMS) and health survey summary form(SF-36) were decreased, and the HAMD and BRMS scores of the patients in the observation group were lower than those of the control group, and the SF-36 score was higher than that of the control group, and the differences were statistically significant(all P < 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group, the difference was statistically significant(P < 0.05). Conclusion The effect of magnesium valproate on bipolar affective disorder patients is obvious. It can improve the quality of life, reduce the condition of mania and depression, and reduce the incidence of adverse reactions. It is worth popularizing and applying in clinic.
引文
[1]童永号.喹硫平治疗双相情感障碍的临床效果[J].中国实用神经疾病杂志,2016,3(1):118-119.
[2]孙静.丙戊酸镁缓释片与碳酸锂缓释片治疗双向情感障碍躁狂发作患者的临床疗效[J].中国药物经济学,2016,5(2):51-53.
[3]于浚玫,白凤凤.喹硫平联合丙戊酸镁治疗双相情感障碍的临床研究[J].中国临床药理学杂志,2016,32(12):1078-1080,1084.
[4]郭晓倩,李艳,彭锐,等.心境障碍女性患者血浆白蛋白、总胆红素和尿酸水平研究[J].海南医学,2017,28(5):761-763.
[5]中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.
[6]胡昌清,朱雪泉,丰雷,等.中国抑郁障碍防治指南(第二版)解读:药物治疗原则[J].中华精神科杂志,2017,50(3):172-174.
[7]李昱.双相情感障碍混合发作与躁狂、抑郁发作患者血清细胞因子的水平比较[J].医学临床研究,2018,35(6):1205-1207.
[8]黄华.齐拉西酮、氯氮平分别联合碳酸锂治疗双向情感障碍躁狂发作的临床疗效与安全性分折[J].北方药学,2017,14(7):127-128.
[9]宋文良.齐拉西酮、氯氮平分别联合碳酸锂治疗双向情感障碍躁狂发作的临床疗效[J].药品评价,2018,15(7):58-60,64.
[10]姜倩.帕罗西汀联合喹硫平治疗双向情感障碍的疗效和安全性[J].中国药物经济学,2017,12(11):67-69.
[11]童容容.丙戊酸钠缓释片联合碳酸锂治疗双向情感障碍躁狂发作的效果[J].上海医药,2017,38(18):25-26,31.
[12]晁阳阳,盛卫勇,赵瑾,等.首发精神分裂症外周血氧化应激状态改变[J].中国神经精神疾病杂志,2016,42(8):449-453.
[13]裴裴,卫汨.高压氧联合精神类药物对脑卒中后抑郁患者血清神经递质及细胞因子含量的影响[J].海南医学院学报,2017,23(23):3306-3309.
[14]费小聪,陈海支,郑燕妮,等.精神分裂症患者NLR、氧化应激参数与精神症状的相关性[J].浙江医学,2017,39(6):449-451,465.
[15]蔡文治,金燕君,王希佳,等.慢性精神分裂症急性期血清非酶抗氧化物浓度与神症状及糖脂代谢的关系[J]中国慢性病预防与控制,2017,25(8):573-577.
[16]Rabadiya S,Bhadada S,Dudhrejiya A,et al.Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors[J].Biomed Pharmacother,2018,119(4):919-927.
[17]付林燕,刘忠纯,相丹,等.单、双相抑郁患者血浆非酶类抗氧化物和甲状腺激素水平研究[J].中国医药导报,2018,15(8):100-103.
[18]张丽,蒙华庆.双相障碍的免疫学研究进展[J].四川精神卫生,2017,30(1):85-89.
[19]胡建高,朱敏.喹硫平对双相情感障碍患者IL-1、IL-10、TNF-α的影响及疗效研究[J].现代诊断与治疗,2016,27(11):2088-2089.
[20]赵敏.双相情感障碍与单相抑郁症患者之间的促炎细胞因子水平的比较分析[J].中国医学创新,2017,14(31):20-23.
[21]代文瑾,张媛,尚翠华,等.急性发作精神分裂症患者血清前炎性因子与临床特征的关系[J].神经疾病与精神卫生,2017,17(8):558-561.
[22]刘潇,闫瑞斌,李敬,等.西酞普兰联合丙戊酸钠对复发双相障碍抑郁发作患者认知功能及血清炎症因子的影响[J].药物评价研究,2017,40(11):1631-1634.
[23]周华.喹硫平单用与合用碳酸锂治疗双相情感障碍躁狂发作的对比研究[J].中外医学研究,2017,15(15):129-130.
[2]孙静.丙戊酸镁缓释片与碳酸锂缓释片治疗双向情感障碍躁狂发作患者的临床疗效[J].中国药物经济学,2016,5(2):51-53.
[3]于浚玫,白凤凤.喹硫平联合丙戊酸镁治疗双相情感障碍的临床研究[J].中国临床药理学杂志,2016,32(12):1078-1080,1084.
[4]郭晓倩,李艳,彭锐,等.心境障碍女性患者血浆白蛋白、总胆红素和尿酸水平研究[J].海南医学,2017,28(5):761-763.
[5]中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.
[6]胡昌清,朱雪泉,丰雷,等.中国抑郁障碍防治指南(第二版)解读:药物治疗原则[J].中华精神科杂志,2017,50(3):172-174.
[7]李昱.双相情感障碍混合发作与躁狂、抑郁发作患者血清细胞因子的水平比较[J].医学临床研究,2018,35(6):1205-1207.
[8]黄华.齐拉西酮、氯氮平分别联合碳酸锂治疗双向情感障碍躁狂发作的临床疗效与安全性分折[J].北方药学,2017,14(7):127-128.
[9]宋文良.齐拉西酮、氯氮平分别联合碳酸锂治疗双向情感障碍躁狂发作的临床疗效[J].药品评价,2018,15(7):58-60,64.
[10]姜倩.帕罗西汀联合喹硫平治疗双向情感障碍的疗效和安全性[J].中国药物经济学,2017,12(11):67-69.
[11]童容容.丙戊酸钠缓释片联合碳酸锂治疗双向情感障碍躁狂发作的效果[J].上海医药,2017,38(18):25-26,31.
[12]晁阳阳,盛卫勇,赵瑾,等.首发精神分裂症外周血氧化应激状态改变[J].中国神经精神疾病杂志,2016,42(8):449-453.
[13]裴裴,卫汨.高压氧联合精神类药物对脑卒中后抑郁患者血清神经递质及细胞因子含量的影响[J].海南医学院学报,2017,23(23):3306-3309.
[14]费小聪,陈海支,郑燕妮,等.精神分裂症患者NLR、氧化应激参数与精神症状的相关性[J].浙江医学,2017,39(6):449-451,465.
[15]蔡文治,金燕君,王希佳,等.慢性精神分裂症急性期血清非酶抗氧化物浓度与神症状及糖脂代谢的关系[J]中国慢性病预防与控制,2017,25(8):573-577.
[16]Rabadiya S,Bhadada S,Dudhrejiya A,et al.Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors[J].Biomed Pharmacother,2018,119(4):919-927.
[17]付林燕,刘忠纯,相丹,等.单、双相抑郁患者血浆非酶类抗氧化物和甲状腺激素水平研究[J].中国医药导报,2018,15(8):100-103.
[18]张丽,蒙华庆.双相障碍的免疫学研究进展[J].四川精神卫生,2017,30(1):85-89.
[19]胡建高,朱敏.喹硫平对双相情感障碍患者IL-1、IL-10、TNF-α的影响及疗效研究[J].现代诊断与治疗,2016,27(11):2088-2089.
[20]赵敏.双相情感障碍与单相抑郁症患者之间的促炎细胞因子水平的比较分析[J].中国医学创新,2017,14(31):20-23.
[21]代文瑾,张媛,尚翠华,等.急性发作精神分裂症患者血清前炎性因子与临床特征的关系[J].神经疾病与精神卫生,2017,17(8):558-561.
[22]刘潇,闫瑞斌,李敬,等.西酞普兰联合丙戊酸钠对复发双相障碍抑郁发作患者认知功能及血清炎症因子的影响[J].药物评价研究,2017,40(11):1631-1634.
[23]周华.喹硫平单用与合用碳酸锂治疗双相情感障碍躁狂发作的对比研究[J].中外医学研究,2017,15(15):129-130.